Enhancing Integration of HIV Testing into TB Control Program and Factors Associated with Refusal of HIV Testing in Taiwan, July 2013–June 2014

DOI: 10.6525/TEB.20170314.33(5).001

Wan-Ting Hsieh1*, Mei-Yu Chiou1, Pin-Hui Lee1, Pei-Chun Chan1,Shiang-Lin Yang1, Chien-Bang Hsu2, Yen-Fang Huang1, Chang-Hsun Chen3

2017 Vol.33 NO.5

Correspondence Author: Wan-Ting Hsieh1*

  • 1Division of Chronic Infectious Diseases, Centers for Disease Control, Ministry of Health and Welfare, Taiwan
  • 2Division of Planning and Coordination, Centers for Disease Control, Ministry of Health and Welfare, Taiwan
  • 3Division of Preparedness and Emerging Infectious Diseases, Centers for Disease Control, Ministry of Health and Welfare, Taiwan

Abstract:

People living with human immunodeficiency virus (PLWH) had 29 times higher risk to develop active tuberculosis (TB) than non-HIV infected persons, and TB was still the leading cause of death among PLWH. Collaborative management of TB/HIV had been recommended by WHO that aimed to reduce the burden of TB and HIV co-infection in affected populations. The TB control program in Taiwan endorsed active HIV counseling and testing, or encouraging HIV testing in TB care facilities by public health staff for TB patients aged 15–49 years old of unknown HIV status since June 27, 2013. A total of 3,533 TB patients were eligible during July 2013 to June 2014 after excluding 63 patients who had been identified HIV co-infection before notification of TB disease. We found that 2,664 TB patients (75.4 %) received HIV testing with the increasing trend of testing proportion during the study period. This intervention identified newly diagnosed HIV infected TB patients and referred them to initiate highly active anti-retroviral therapy (HAART) treatment. Among them, up to 89.7% received HAART. The main reasons that patients refused HIV testing were having low risk to get HIV infection (42.3%); and not important to test HIV (36.1%). In the future, we suggest enhancing TB screening in HIV control program and isoniazid preventive therapy (IPT) for PLWH.

Keywords:Tuberculosis (TB), People living with human immunodeficiency virus (PLWH), HIV testing